
COVID-19 to reshape R&D investments toward infectious diseases
Infectious diseases have been largely forgotten by Pharma R&D and investors, as chronic diseases, cancer and rare diseases gave better...
COVID-19 to reshape R&D investments toward infectious diseases
Post Brexit, will UK MedTech take back control or align with key markets ?
Germany bets on its Biotechs and mRNA COVID-19 vaccines
GENFIT moves focus to promising NASH diagnostic
Biosimilars finally taking off in the US
UCB’s Bimekizumab to reshape psoriasis market